Introduction
Duchenne muscular dystrophy is a fatal disorder characterized by progressive muscular weakness, wasting, and severe muscle contractures in later disease stages. Muscle biopsy reveals conspicuous myofiber degeneration and fibrosis substituting muscle tissue. We quantitatively determined mRNA of the potent fibrogenic cytokine transforming growth factor-j1 by quantitative PCR in 15 Duchenne muscular dystrophy, 13 Becker muscular dystrophy, 11 spinal muscular atrophy patients, and 16 controls. Higher transforming growth factor-fit expression was greater in Duchenne muscular dystrophy patients than controls (P = 0.012) and Becker patients (P = 0.03). Fibrosis was significantly more prominent in Duchenne muscular dystrophy than Becker muscular dystrophy, spinal muscular atrophy, and controls. The proportion of connective tissue in muscle biopsies increased progressively with age in Duchenne muscular dystrophy patients, while transforming growth factorfi1 levels peaked at 2 and 6 yr of age. Transforming growth factor-ftP protein was also detected by immunocytochemistry and immunoblotting. Our findings suggest that transforming growth factor-fi stimulates fibrosis in Duchenne muscular dystrophy. Expression of transforming growth factor-ft. in the early stages of Duchenne muscular dystrophy may be critical in initiating muscle fibrosis and antifibrosis treatment could slow progression of the disease, increasing the utility of gene therapy. (J. Clin. Invest. 1995.
96:1137-1144.) Key words: transforming growth factor-fi -Duchenne muscular dystrophy * Becker muscular dystrophy * fibrosis * polymerase chain reaction 1 . Abbreviations used in this paper: bFGF, basic fibroblast growth factor; BMD, Becker muscular dystrophy; DMD, Duchenne muscular dystrophy; Q-PCR quantitative PCR; SMA, spinal muscular atrophy; TGF-#I1, transforming growth factor-3il.
Duchenne muscular dystrophy (DMD)' is an X-linked recessive disease, affecting 1 in every 3,500 males in all populations. Progressive muscular weakness and wasting confine DMD patients to a wheelchair before the age of 15 and the disease terminates fatally around the end of the second decade (1, 2). The severe DMD phenotype is caused by mutations in the dystrophin gene (3) , which lead to the absence of the cytoskeletal protein dystrophin (427 kD), normally localized at the cytoplasmic face of the sarcolemma of skeletal muscle fibers (4) . Characteristic histological findings in DMD are degeneration of fibers due to segmental necrosis, regeneration, and excessive connective tissue proliferation (5) . After the discovery of dystrophin (4), the most favored explanation for the muscle degeneration was that focal discontinuities in the dystrophin-deficient membrane led, under specific conditions, to abnormal intracellular Ca2" influx resulting in segmental myofiber destruction (6, 7) .
A proportion of samples from DMD muscles shows a mononuclear cell infiltrate consisting of macrophages, T lymphocytes, and natural killer/killer cells (8, 9) . Gorospe et al. have recently reported large numbers of mast cells at the endomysium of dystrophic muscle, in the same area as grouped necrosis, suggesting that mast cell degranulation plays a role in inducing myofiber death ( 10, 11 ).
Myofiber degeneration is followed by muscle fibrosis, predominantly composed of type HI collagen and involving the endomysium and perimysium (12) . Fibrosis may be evident at the early stage and progresses with the disease.
Transforming growth factor-fI3 (TGF-fi1) is a multifunctional protein (13) which plays an important role in inflammation (14) (15) (16) , in wound healing, and fibrosis (17) . Studies on lung fibrosis (18) and liver cirrhosis (19) (both chronic, progressive, and fatal organ diseases) have shown that high levels of TGF-,61 are present at sites of extracellular matrix expansion. The aim of the present study was to determine whether TGF-P 1 mRNA was expressed in Xp2l dystrophy muscles, and to relate its expression to patient age and degree of connective tissue proliferation. Results TGF-,31 mRNA was detected by RNA-PCR in muscle samples from all DMD, BMD, and SMA patients as well as from normal controls (Fig. 1 a) . The cDNA samples were also used to detect actin transcripts as check for successful PCR amplification (Fig.  1 b) . The intensity of actin transcript staining was similar in all samples, while the intensity of TGF-3il transcript staining was variable. We therefore decided to quantify TGF-,B1 mRNA expression using Q-PCR. Fig. 2 shows a Q-PCR gel for a DMD muscle sample (Fig. 2 a) along with a representative plot used to determine the amount of TGF-/ I -specific mRNA (Fig. 2  b) . We found higher quantities of TGF-,B1 in DMD (mean 16.7±25.4 fg/200 ng total RNA) than in BMD, SMA, and control muscles (Fig. 3 a) . In all SMA patients TGF-,B1 transcripts were barely quantifiable, and in controls they were some- The results of the analysis of connective tissue proliferation in muscle are presented in Fig. 3 b. The proportion of connective tissue in muscle samples was higher in DMD patients than in BMD or SMA patients, and controls (statistical data given in legend to Fig. 3 b) .
After grouping the patients according to age at biopsy (< 2 yr, between 2 and 6 yr, and 7 or more yr), levels of TGF-f31
and connective tissue proliferation were compared. In DMD the proportional connective tissue in muscle increased progressively with age, while TGF-fil levels peaked between 2 and 6 yr (Fig. 4 a) . In BMD the trends for connective tissue proliferation and TGF-f31 levels were similar to those in DMD, but absolute values were lower (Fig. 4 b) . In SMA patients there was a progressive increase in connective tissue proliferation but variation in TGF-f13 levels were not significant (Fig. 4 c) .
In all DMD patients, TGF-,f1 positive immunostaining was observed in thickened and fibrotic perimysial connective tissue branches. TGF-P 1 positivity was also detected in circumscribed areas of the endomysial connective tissue. Rarely, in areas corresponding to endomysial positivity, few mononuclear cells were observed on hematoxylin and eosin-stained adjacent sections (Fig. 5) . TGF-f31 positivity, exclusively localized in the perimysial connective tissue, was also observed in BMD and SMA patient muscle, while normal control muscle did not show any TGF-f13 positivity (data not shown). TGF-fi1 expression was also tested with immunoblot using a monoclonal antibody directed against the active form. The strongest signal was seen in DMD muscle; however, a positive spot was also seen in BMD and SMA, whereas in normal controls the active TGF-f31 signal was insubstantial (Fig. 6 ). Supernatants from PBLs, cultured in serum-free media in the presence of PHA, were positive on blots and served as positive controls.
Discussion
Connective tissue proliferation in muscles is a major characteristic of DMD patients and is considered to be secondary to the degeneration of muscle tissue. The phenomenon may be viewed irreversible derangement of muscle tissue organization (2, 5, 12) . Fibrosis hinders nutritional support of myofibers, particularly in the advanced stages when they become physically isolated from blood supply (2) . This stage correlates with development of muscular contractures (2) . Connective tissue proliferation is a feature of several diseases including liver cirrhosis, glomerulonephritis, idiopathic lung fibrosis, and systemic sclerosis in which excessive development of fibrotic tissue correlates with disease irreversibility (for a recent review see reference 25). In these pathologies focal release of fibrogenic cyto- kines is known to be a key element in collagen synthesis and fibroblast proliferation (26) . Although TGF-,B1 gene is up-regulated in response to tissue injury and thought to be the cytokine most implicated in fibrosis (25, 27, 28) , other cytokines, including platelet-derived growth factor, basic fibroblast growth factor (bFGF), tumor necrosis factor and interleukin-1, probably exert synergistic or coordinated effects on development of fibrosis. However, it seems that TGF-3 1 alone is able to promote increased extracellular matrix deposition ( 15, 29 times more sensitive than northern blotting (34) . Such transcripts were found in all muscle samples including controls (Fig. 1) . We then quantified TGF-PI3 transcript levels using Q-PCR (21, 35) . We found that TGF-fL1 transcript concentration in DMD muscle was significantly greater than in controls (P = 0.012) and BMD patients (P = 0.0316) (Fig. 3 a) (Fig. 3 b) .
It is known that TGF-,/1 femtomolar concentrations are strongly chemotactic for neutrophils, T cells, monocytes and fibroblasts; these cells may become activated and produce their own TGF-/31, thus amplifying its fibrotic effect (25, 29) . D'Amore et al. reported that serum levels of bFGF, another fibrogenic cytokine, were significantly increased in 61% of DMD patients, all of whom fell in the 4-9 yr age group, suggesting that bFGF is involved in the pathogenesis of muscular dystrophy (36) . We have found that TGF-/61 levels increased with age up to 6 yr and afterwards declined to very low levels, while connective tissue proliferation continued to increase (Fig.  4 a) . This trend is similar to that D'Amore reported for bFGF (36) . Thus both these cytokines are expressed in the early stages of fibrosis and we conjecture that they are involved in this process, while in later stages of DMD, fibrosis may be perpetuated by other mediators or by autocrine processes, as is the case in hepatic fibrosis (37) .
It has been reported that TGF-/31 mRNA is constitutively expressed in monocytes but only after their activation do these cells secrete the TGF-/31 protein, suggesting a crucial posttranscriptional regulation of protein expression (38) . It should be emphasized that in DMD, mononuclear cell infiltrates, composed of macrophages, activated T lymphocytes and natural killer cells, are occasionally observed, mainly at the site of endomysial inflammation (8, 9, 39) . At these sites, the infiltrating cells may be partially responsible for local secretion or activation of fibrogenic cytokines (13, 16), including TGF-/31, which is able to up-regulate its own synthesis (40) . Our results show that TGF-3il is present in the endomysium of DMD muscles; and that this localization differs from that found in BMD and SMA, where TGF-/31 is located in the perimysium. Our findings confirm, therefore, Yamazaki et al.'s report of TGF-/31 in the endomysium (33) but not in the muscle fibers; these authors used parafin-embedded sections, whereas we examined frozen material.
After an initial stimulatory effect on inflammatory cells, TGF-/1 exerts an antiinflammatory action, inhibiting synthesis of TNF-a and IL-i (41, 42). On a cytokine profile examination of DMD muscles we were not able to detect, by RNA-PCR, IL-la transcripts, while TNF-a transcripts were detected in a minority (23%) of patients (43) (10) in their analysis of mast cell involvement in dystrophic muscle degeneration. An antifibrotic approach has been successful in the kidney, skin, lung, brain, joint, and arterial wall fibrotic diseases (47) (48) (49) (50) (51) (52) (53) . In this regard we note that empirical treatment of DMD patients with steroids (54) or cyclosporine A (55) has produced a slight and transient improvements of muscle strength which may be related, at least in part, to an effect on inflammation-related release of fibrogenic cytokines. However, it should be remembered that cyclosporine A in vitro increases TGF-,31 mRNA expression even though an immunosuppressive effect is exerted ultimately (21) . Finally, we note that the presence of an active fibrogenic process in dystrophic muscles may render therapy for the replacement of dystrophin less feasible and less effective.
